Table 3.
Functional enrichment of the identified DEG results using Cluego, showing the associated genes with the pathways and the percentage of mapped genes from the total number of genes from the term.
| Pathway | Corrected p Value | % Genes | N Genes | Associated Genes |
|---|---|---|---|---|
| HIV1 infection | 1.6 × 10−5 | 4.25 | 9 | ATM, BCL2L1, CFL2, CHUK, CRKL, CUL5, MAPK9, NFKBIA, TRAF6 |
| Pathways in cancer | 1.55 × 10−4 | 2.26 | 12 |
BCL2L1, CCDC6, CHUK, CRKL, EGLN1, FZD4, LRP6, MAPK9, NFKBIA, ROCK2, TRAF6, TXNRD2 |
| NF-kappa B signalling pathway | 1.9 × 10−4 | 5.77 | 6 | ATM, BCL2L1, CHUK, CSNK2A1, NFKBIA, TRAF6 |
| Shigellosis | 4.09 × 10−4 | 3.24 | 8 | ATM, BCL2L1, CHUK, CRKL, MAPK9, NFKBIA, ROCK2, TRAF6 |
| Measles virus infection | 7.56 × 10−4 | 4.35 | 6 | BCL2L1, CHUK, CSNK2A1, MAPK9, NFKBIA, TRAF6 |
| Yersinia infection | 7.86 × 10−4 | 4.38 | 6 | CHUK, CRKL, MAPK9, NFKBIA, ROCK2, TRAF6 |
| Brain-derived neurotrophic factor (BDNF) signalling pathway | 7.98 × 10−4 | 4.17 | 6 | CHUK, CSNK2A1, MAPK9, NFKBIA, NTRK3, TRAF6 |
| MAPK signalling pathway | 9.02 × 10−4 | 2.72 | 8 | CHUK, CRKL, CSF1, DUSP1, ERBB3, FLT1, MAPK9, TRAF6 |
| Lipid and atherosclerosis | 5.58 × 10−3 | 2.79 | 6 | [BCL2L1, CHUK, MAPK9, NFKBIA, ROCK2, TRAF6] |
| Malignant pleural mesothelioma | 9.83 × 10−3 | 1.79 | 8 | ATM, CSF1, CSNK2A1, FLT1, LRP6, MAPK9, RNF2, SAV1 |
| Alzheimer disease | 1.22 × 10−2 | 1.56 | 6 | CHUK, CSF1, CSNK2A1, FZD4, LRP6, MAPK9 |
| IL-18 signalling pathway | 1.32 × 10−2 | 2.15 | 6 | BCL2L1, CHUK, FOXN3, MAPK9, NFKBIA, TRAF6 |
| Pathways of neurodegeneration | 1.88 × 10−2 | 1.47 | 7 | BCL2L1, CSF1, CSNK2A1, FZD4, LRP6, LRRK2, MAPK9 |
| VEGFA-VEGFR2 signalling pathway | 2.45 × 10−2 | 1.59 | 7 | BCL2L1, CTNND1, FLT1, MAPK9, NFKBIA, PNP, ROCK2 |
| PI3K-Akt signalling pathway | 2.52 × 10−2 | 1.69 | 6 | BCL2L1, CHUK, CSF1, ERBB3, FLT1, PHLPP1 |